Wilms tumor (nephroblastoma), version 2.2021

Frank Balis; Daniel M. Green; Clarke Anderson; Shelly Cook; Jasreman Dhillon; Kenneth Gow; Susan Hiniker; Rama Jasty-Rao; Chi Lin; Harold Lovvorn; Iain MacEwan; Julian Martinez-Agosto; Elizabeth Mullen; Erin S. Murphy; Mark Ranalli; Daniel Rhee; Denise Rokitka; Elisabeth Lisa Tracy; Tamara Vern-Gross; Michael F. Walsh; Amy Walz; Jonathan Wickiser; Matthew Zapala; Ryan A. Berardi; Miranda Hughes

doi:10.6004/jnccn.2021.0037

Wilms tumor (nephroblastoma), version 2.2021

Frank Balis, Daniel M. Green, Clarke Anderson, Shelly Cook, Jasreman Dhillon, Kenneth Gow, Susan Hiniker, Rama Jasty-Rao, Chi Lin, Harold Lovvorn, Iain MacEwan, Julian Martinez-Agosto, Elizabeth Mullen, Erin S. Murphy, Mark Ranalli, Daniel Rhee, Denise Rokitka, Elisabeth Lisa Tracy, Tamara Vern-Gross, Michael F. WalshAmy Walz, Jonathan Wickiser, Matthew Zapala, Ryan A. Berardi, Miranda Hughes

Pediatrics

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

The NCCN Guidelines for Wilms Tumor focus on the screening, diagnosis, staging, treatment, and management of Wilms tumor (WT, also known as nephroblastoma). WT is the most common primary renal tumor in children. Five-year survival is more than 90% for children with all stages of favorable histology WT who receive appropriate treatment. All patients with WT should be managed by a multidisciplinary team with experience in managing renal tumors; consulting a pediatric oncologist is strongly encouraged. Treatment of WT includes surgery, neoadjuvant or adjuvant chemotherapy, and radiation therapy (RT) if needed. Careful use of available therapies is necessary to maximize cure and minimize long-term toxicities. This article discusses the NCCN Guidelines recommendations for favorable histology WT.

Original language	English (US)
Pages (from-to)	945-977
Number of pages	33
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	19
Issue number	8
DOIs	https://doi.org/10.6004/jnccn.2021.0037
State	Published - Aug 2021

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2021.0037

Cite this

Balis, F., Green, D. M., Anderson, C., Cook, S., Dhillon, J., Gow, K., Hiniker, S., Jasty-Rao, R., Lin, C., Lovvorn, H., MacEwan, I., Martinez-Agosto, J., Mullen, E., Murphy, E. S., Ranalli, M., Rhee, D., Rokitka, D., Tracy, E. L., Vern-Gross, T., ... Hughes, M. (2021). Wilms tumor (nephroblastoma), version 2.2021. JNCCN Journal of the National Comprehensive Cancer Network, 19(8), 945-977. https://doi.org/10.6004/jnccn.2021.0037

@article{351d60eca93d4b7086fc0671f33d7be8,

title = "Wilms tumor (nephroblastoma), version 2.2021",

abstract = "The NCCN Guidelines for Wilms Tumor focus on the screening, diagnosis, staging, treatment, and management of Wilms tumor (WT, also known as nephroblastoma). WT is the most common primary renal tumor in children. Five-year survival is more than 90% for children with all stages of favorable histology WT who receive appropriate treatment. All patients with WT should be managed by a multidisciplinary team with experience in managing renal tumors; consulting a pediatric oncologist is strongly encouraged. Treatment of WT includes surgery, neoadjuvant or adjuvant chemotherapy, and radiation therapy (RT) if needed. Careful use of available therapies is necessary to maximize cure and minimize long-term toxicities. This article discusses the NCCN Guidelines recommendations for favorable histology WT.",

author = "Frank Balis and Green, {Daniel M.} and Clarke Anderson and Shelly Cook and Jasreman Dhillon and Kenneth Gow and Susan Hiniker and Rama Jasty-Rao and Chi Lin and Harold Lovvorn and Iain MacEwan and Julian Martinez-Agosto and Elizabeth Mullen and Murphy, {Erin S.} and Mark Ranalli and Daniel Rhee and Denise Rokitka and Tracy, {Elisabeth Lisa} and Tamara Vern-Gross and Walsh, {Michael F.} and Amy Walz and Jonathan Wickiser and Matthew Zapala and Berardi, {Ryan A.} and Miranda Hughes",

note = "Publisher Copyright: {\textcopyright} National Comprehensive Cancer Network, Inc. 2021.",

year = "2021",

month = aug,

doi = "10.6004/jnccn.2021.0037",

language = "English (US)",

volume = "19",

pages = "945--977",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "8",

}

Balis, F, Green, DM, Anderson, C, Cook, S, Dhillon, J, Gow, K, Hiniker, S, Jasty-Rao, R, Lin, C, Lovvorn, H, MacEwan, I, Martinez-Agosto, J, Mullen, E, Murphy, ES, Ranalli, M, Rhee, D, Rokitka, D, Tracy, EL, Vern-Gross, T, Walsh, MF, Walz, A, Wickiser, J, Zapala, M, Berardi, RA & Hughes, M 2021, 'Wilms tumor (nephroblastoma), version 2.2021', JNCCN Journal of the National Comprehensive Cancer Network, vol. 19, no. 8, pp. 945-977. https://doi.org/10.6004/jnccn.2021.0037

TY - JOUR

T1 - Wilms tumor (nephroblastoma), version 2.2021

AU - Balis, Frank

AU - Green, Daniel M.

AU - Anderson, Clarke

AU - Cook, Shelly

AU - Dhillon, Jasreman

AU - Gow, Kenneth

AU - Hiniker, Susan

AU - Jasty-Rao, Rama

AU - Lin, Chi

AU - Lovvorn, Harold

AU - MacEwan, Iain

AU - Martinez-Agosto, Julian

AU - Mullen, Elizabeth

AU - Murphy, Erin S.

AU - Ranalli, Mark

AU - Rhee, Daniel

AU - Rokitka, Denise

AU - Tracy, Elisabeth Lisa

AU - Vern-Gross, Tamara

AU - Walsh, Michael F.

AU - Walz, Amy

AU - Wickiser, Jonathan

AU - Zapala, Matthew

AU - Berardi, Ryan A.

AU - Hughes, Miranda

PY - 2021/8

Y1 - 2021/8

N2 - The NCCN Guidelines for Wilms Tumor focus on the screening, diagnosis, staging, treatment, and management of Wilms tumor (WT, also known as nephroblastoma). WT is the most common primary renal tumor in children. Five-year survival is more than 90% for children with all stages of favorable histology WT who receive appropriate treatment. All patients with WT should be managed by a multidisciplinary team with experience in managing renal tumors; consulting a pediatric oncologist is strongly encouraged. Treatment of WT includes surgery, neoadjuvant or adjuvant chemotherapy, and radiation therapy (RT) if needed. Careful use of available therapies is necessary to maximize cure and minimize long-term toxicities. This article discusses the NCCN Guidelines recommendations for favorable histology WT.

AB - The NCCN Guidelines for Wilms Tumor focus on the screening, diagnosis, staging, treatment, and management of Wilms tumor (WT, also known as nephroblastoma). WT is the most common primary renal tumor in children. Five-year survival is more than 90% for children with all stages of favorable histology WT who receive appropriate treatment. All patients with WT should be managed by a multidisciplinary team with experience in managing renal tumors; consulting a pediatric oncologist is strongly encouraged. Treatment of WT includes surgery, neoadjuvant or adjuvant chemotherapy, and radiation therapy (RT) if needed. Careful use of available therapies is necessary to maximize cure and minimize long-term toxicities. This article discusses the NCCN Guidelines recommendations for favorable histology WT.

UR - http://www.scopus.com/inward/record.url?scp=85113306870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85113306870&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2021.0037

DO - 10.6004/jnccn.2021.0037

M3 - Review article

C2 - 34416707

AN - SCOPUS:85113306870

SN - 1540-1405

VL - 19

SP - 945

EP - 977

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 8

ER -

Wilms tumor (nephroblastoma), version 2.2021

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this